[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Acinetobacter Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 173 pages | ID: A875BAF3CB93EN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Acinetobacter Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acinetobacter Infections - Drugs In Development, 2022, provides an overview of the Acinetobacter Infections (Infectious Disease) pipeline landscape.

Acinetobacter is a gram-negative coccobacillus. Acinetobacter infections are uncommon but, when they occur, usually involve organ systems that have a high fluid content (respiratory tract, CSF, peritoneal fluid, urinary tract). Symptoms include fever (high body temperature), red, swollen, warm or painful skin areas or wounds. Predisposing factors include weak immune system, poor hygiene and recent surgery or procedure.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acinetobacter Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Acinetobacter Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acinetobacter Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Acinetobacter Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 8, 45, 21 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 7 molecules, respectively.

Acinetobacter Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acinetobacter Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Acinetobacter Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acinetobacter Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acinetobacter Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acinetobacter Infections (Infectious Disease)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acinetobacter Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acinetobacter Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Acinetobacter Infections - Overview
Acinetobacter Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Acinetobacter Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Acinetobacter Infections - Companies Involved in Therapeutics Development
Acinetobacter Infections - Drug Profiles
Acinetobacter Infections - Dormant Projects
Acinetobacter Infections - Discontinued Products
Acinetobacter Infections - Product Development Milestones
Featured News & Press Releases
Jun 13, 2022: Entasis Therapeutics presents data on Sulbactam-Durlobactam at 2022 ASM Microbe Annual Conference
May 17, 2022: Entasis Therapeutics presents data highlights from phase 3 ATTACK trial at 2022 American Thoracic Society Annual Conference
Apr 26, 2022: Entasis Therapeutics presents efficacy and safety data from landmark phase 3 ATTACK Trial at ECCMID 2022 Conference
Apr 21, 2022: Qpex Biopharma announces presentation of Clinical Data for Lipopeptide QPX9003 at ECCMID 2022 Meeting
Apr 18, 2022: Entasis Therapeutics presents SUL-DUR topline data from phase 3 ATTACK Trial at ECCMID 2022 Conference
Oct 19, 2021: Entasis reports positive data from Phase III Acinetobacter drug trial
Aug 10, 2021: Entasis Therapeutics to host expert perspectives webinar on Acinetobacter infections
Jul 27, 2021: Entasis Therapeutics and Zai Lab Complete patient enrollment in the ATTACK phase 3 registrational clinical trial of sulbactam-durlobactam
Jun 18, 2021: Monash University’s new antibiotic against superbugs starts US trial
Jun 18, 2021: Entasis Therapeutics presents data on SUL-DUR at World Microbe Forum
Mar 04, 2021: ARCH scientist publishes paper showing pre-clinical efficacy of AB569 in eradicating multi-drug resistant pathogens Acinetobacter baumannii and Acinetobacter spp
Jan 26, 2021: Entasis Therapeutics announces sulbactam-durlobactam expanded access program for patients in the U.S.
Oct 14, 2020: Entasis Therapeutics highlights multiple data presentations at Virtual ID Week
Jul 27, 2020: Venatorx Pharmaceuticals awarded up to $44.2 million to advance novel inhibitors of penicillin binding proteins targeting WHO critical priority pathogen
May 18, 2020: Zai Lab announces first chinese patient dosed in the global phase 3 ATTACK trial of Sulbactam-Durlobactam for patients with Carbapenem-Resistant Acinetobacter Infections
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Acinetobacter Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Acinetobacter Infections - Pipeline by AbGenics Life Sciences Pvt Ltd, 2022
Acinetobacter Infections - Pipeline by Adaptive Phage Therapeutics Inc, 2022
Acinetobacter Infections - Pipeline by AGILeBiotics BV, 2022
Acinetobacter Infections - Pipeline by Alterity Therapeutics Ltd, 2022
Acinetobacter Infections - Pipeline by Antabio SAS, 2022
Acinetobacter Infections - Pipeline by Appili Therapeutics Inc, 2022
Acinetobacter Infections - Pipeline by Arch Biopartners Inc, 2022
Acinetobacter Infections - Pipeline by Aridis Pharmaceuticals Inc, 2022
Acinetobacter Infections - Pipeline by Armata Pharmaceuticals Inc, 2022
Acinetobacter Infections - Pipeline by Asieris Pharmaceuticals Co Ltd, 2022
Acinetobacter Infections - Pipeline by AstraZeneca Plc, 2022
Acinetobacter Infections - Pipeline by Atterx Biotherapeutics Inc, 2022
Acinetobacter Infections - Pipeline by Aurora Oncology Inc, 2022
Acinetobacter Infections - Pipeline by Bioharmony Therapeutics Inc, 2022
Acinetobacter Infections - Pipeline by Biological Anti-Infective Medicines LLC, 2022
Acinetobacter Infections - Pipeline by Biomendics LLC, 2022
Acinetobacter Infections - Pipeline by Bioversys AG, 2022
Acinetobacter Infections - Pipeline by Bugworks Research India Pvt Ltd, 2022
Acinetobacter Infections - Pipeline by Celdara Medical LLC, 2022
Acinetobacter Infections - Pipeline by Centauri Therapeutics Ltd, 2022
Acinetobacter Infections - Pipeline by Clarametyx Biosciences Inc, 2022
Acinetobacter Infections - Pipeline by ContraFect Corp, 2022
Acinetobacter Infections - Pipeline by Danuvius BioSciences, 2022
Acinetobacter Infections - Pipeline by Debiopharm International SA, 2022
Acinetobacter Infections - Pipeline by Entasis Therapeutics Holdings Inc, 2022
Acinetobacter Infections - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Acinetobacter Infections - Pipeline by Fedora Pharmaceuticals Inc, 2022
Acinetobacter Infections - Pipeline by Hsiri Therapeutics LLC, 2022
Acinetobacter Infections - Pipeline by Idorsia Pharmaceutical Ltd, 2022
Acinetobacter Infections - Pipeline by Infextious Therapeutic, 2022
Acinetobacter Infections - Pipeline by Inhibrx Inc, 2022
Acinetobacter Infections - Pipeline by KBP Biosciences Co Ltd, 2022
Acinetobacter Infections - Pipeline by Linnaeus Bioscience Inc, 2022
Acinetobacter Infections - Pipeline by Meiji Seika Pharma Co Ltd, 2022
Acinetobacter Infections - Pipeline by Melinta Therapeutics Inc, 2022
Acinetobacter Infections - Pipeline by MetalloBio Ltd, 2022
Acinetobacter Infections - Pipeline by Mutabilis SA, 2022
Acinetobacter Infections - Pipeline by Nektr Technologies Ltd, 2022
Acinetobacter Infections - Pipeline by Neoculi Pty Ltd, 2022
Acinetobacter Infections - Pipeline by Novabiotics Ltd, 2022
Acinetobacter Infections - Pipeline by Omnix Medical Ltd, 2022
Acinetobacter Infections - Pipeline by Oxford Drug Design Ltd, 2022
Acinetobacter Infections - Pipeline by Pedanius Therapeutics Ltd, 2022
Acinetobacter Infections - Pipeline by Peptilogics Inc, 2022
Acinetobacter Infections - Pipeline by Pylum Biosciences Inc, 2022
Acinetobacter Infections - Pipeline by Qpex Biopharma Inc, 2022
Acinetobacter Infections - Pipeline by Recce Pharmaceuticals Ltd, 2022
Acinetobacter Infections - Pipeline by Redx Pharma Plc, 2022
Acinetobacter Infections - Pipeline by RMH Sciences LLC, 2022
Acinetobacter Infections - Pipeline by Shanghai Space Peptides Pharmaceutical Co Ltd, 2022
Acinetobacter Infections - Pipeline by Shionogi & Co Ltd, 2022
Acinetobacter Infections - Pipeline by Spero Therapeutics Inc, 2022
Acinetobacter Infections - Pipeline by Spexis AG, 2022
Acinetobacter Infections - Pipeline by Summit Therapeutics Inc, 2022
Acinetobacter Infections - Pipeline by Techulon Inc, 2022
Acinetobacter Infections - Pipeline by Vaxdyn SL, 2022
Acinetobacter Infections - Pipeline by VenatoRx Pharmaceuticals Inc, 2022
Acinetobacter Infections - Pipeline by Venus Medicine Research Centre, 2022
Acinetobacter Infections - Pipeline by Vitas Pharma Research Pvt Ltd, 2022
Acinetobacter Infections - Pipeline by Xellia Pharmaceuticals ApS, 2022
Acinetobacter Infections - Dormant Projects, 2022
Acinetobacter Infections - Discontinued Products, 2022

LIST OF FIGURES

Number of Products under Development for Acinetobacter Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022


More Publications